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A B S T R A C T
Purpose
Recent studies suggest that tumor-infiltrating lymphocytes (TILs) are associated with disease-free
(DFS) and overall survival (OS) in operable triple-negative breast cancer (TNBC). We seek to
validate the prognostic impact of TILs in primary TNBCs in two adjuvant phase III trials conducted
by the Eastern Cooperative Oncology Group (ECOG).
Patients and Methods
Full-face hematoxylin and eosin–stained sections of 506 tumors from ECOG trials E2197 and
E1199 were evaluated for density of TILs in intraepithelial (iTILs) and stromal compartments
(sTILs). Patient cases of TNBC from E2197 and E1199 were randomly selected based on
availability of sections. For the primary end point of DFS, association with TIL scores was
determined by fitting proportional hazards models stratified on study. Secondary end points were
OS and distant recurrence–free interval (DRFI). Reporting recommendations for tumor marker
prognostic studies criteria were followed, and all analyses were prespecified.
Results
The majority of 481 evaluable cancers had TILs (sTILs, 80%; iTILs, 15%). With a median follow-up
of 10.6 years, higher sTIL scores were associated with better prognosis; for every 10% increase
in sTILs, a 14% reduction of risk of recurrence or death (P  .02), 18% reduction of risk of distant
recurrence (P  .04), and 19% reduction of risk of death (P  .01) were observed. Multivariable
analysis confirmed sTILs to be an independent prognostic marker of DFS, DRFI, and OS.
Conclusion
In two national randomized clinical trials using contemporary adjuvant chemotherapy, we confirm
that stromal lymphocytic infiltration constitutes a robust prognostic factor in TNBCs. Studies
assessing outcomes and therapeutic efficacies should consider stratification for this parameter.
J Clin Oncol 32:2959-2966. © 2014 by American Society of Clinical Oncology
INTRODUCTION
Evidence suggests that the immune system influ-
ences breast cancer prognosis.1 Lymphocytic infil-
trates in breast cancer were described decades ago;
they are most prominent in aggressive tumors and
linked tooutcome in these subtypes.2More recently,
tumor-infiltrating lymphocytes (TILs) have been
evaluated in randomized trials using contemporary
chemotherapy; these studies have confirmed that
TILs are most frequently found in highly prolifera-
tive tumors (triple-negative [TNBC] and human
epidermal growth factor receptor 2 [HER2] –positive
breast cancers) and that their presence at diagnosis
is associated with pathologic response to neoad-
juvant therapy as well as disease-free (DFS) and
overall survival (OS) after adjuvant chemothera-
py in certain subtypes.3-5 Specifically, Loi et al4
evaluated the relationship between TILs at diag-
nosis with clinical outcome in the BIG 02-98 ad-
juvant phase III trial and showed a significant
association in TNBC. If confirmed in an indepen-
dent study, this would suggest that routine assess-
ment and quantification of TILs could provide
clinically meaningful prognostic information
in TNBC.
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We herein describe a prospective-retrospective validation study
performed in accordance with guidelines recommended by Simon et
al6 and theReportingRecommendations forTumorMarkerPrognos-
tic Studies (REMARK) criteria.7 The purpose of our study was to
provide confirmatory evidence of clinical validity for TILs as a prog-
nostic biomarker in TNBC. We used archived samples from two
adjuvant phase III trials coordinated by the Eastern Cooperative
Group (ECOG) in collaboration with the North American Breast
Cancer Groups and evaluated the prognostic utility of TILs within
intraepithelial (iTILs) and stromal compartments (sTILs) in TNBCs
treated with adjuvant anthracycline-containing chemotherapy.
PATIENTS AND METHODS
Study Patients
TIL analysis was retrospectively performed on prospectively collected
formalin-fixed paraffin-embedded hematoxylin and eosin (HE) –stained sec-
tions from twoECOG-sponsored randomized, prospective phase III adjuvant
trials (E2197 and E1199). All samples were collected at baseline from the
surgical specimens. Patients enrolled onto both trials had consented to use of
their tumor tissue for research purposes, and this study was approved by the
Breast Cancer Intergroup of North America (TBCI) committee. In addition,
institutional review board approval was obtained from Indiana University.
In E2197, 2,952womenwith T1c to T3N0or T1-3N1 breast cancerwere
enrolled between July 1998 and January 2000 and randomly assigned to doxo-
rubicin (60 mg/m2) plus either cyclophosphamide (600 mg/m2) or docetaxel
(60 mg/m2) once every 3 weeks for four cycles. For this analysis, we used a
subset of 776 tumors that had central evaluation of histologic grade and
estrogen receptor (ER), progesterone receptor (PR), and HER2 by immuno-
histochemistry on tissue microarrays as previously described8; of these, 250
samples were TNBCs, and 191 of these still had slides available for review
(AppendixFigA1, onlineonly). ERandPRwere considerednegativeusing the
American Society of Clinical Oncology (ASCO)/College of American Pathol-
ogists (CAP) guidelines ( 1%).9
In E1199, 5,052 women with T1-3N1-2 or T2-3N0 breast cancer were
enrolled between October 1999 and January 2002 and randomly assigned to
Table 1. Characteristics of Patient Subsets Included in Analysis and Corresponding Population for Each Study
Characteristic
E1199
(n  291)
E2197
(n  190)
Total
(N  481)
All TNBCs
in E1199
(n  926)
All Hormone
Receptor–Negative
BCs in E2197
(n  922)†
No. % No. % No. % No. % No. %
Age, years
24-40 66 22.7 38 20.0 104 21.6 198 21.4 177 19.2
41-50 108 37.1 68 35.8 176 36.6 335 36.2 330 35.8
51-60 77 26.5 60 31.6 137 28.5 260 28.1 280 30.4
61-85 40 13.7 24 12.6 64 13.3 133 14.4 135 14.6
Menopausal status
Premenopausal 164 56.4 95 50.0 259 53.8 489 52.8 466 50.5
Postmenopausal 127 43.6 95 50.0 222 46.2 437 47.2 456 49.5
No. of lymph nodes
0 56 19.2 141 74.2 197 41.0 182 19.7 717 77.8
1-3 150 51.5 49 25.8 199 41.4 484 52.4 205 22.2
 3 85 29.2 0 0.0 85 17.7 258 27.9 0 0.0
Tumor size, cm
0.1-2.0 75 25.8 82 43.2 157 32.6 243 26.3 416 45.1
2.1-5.0 184 63.2 99 52.1 283 58.8 586 63.4 466 50.5
 5.0 32 11.0 9 4.7 41 8.5 95 10.3 40 4.3
Receptor status
Triple negative 291 100.0 190 100.0 481 100.0 926 100.0 NA†
Primary surgery
Local excision 137 47.1 114 60.0 251 52.2 408 44.1 520 56.4
Mastectomy 154 52.9 76 40.0 230 47.8 517 55.9 402 43.6
Race
White 243 83.5 160 84.2 403 83.8 728 78.6 776 84.3
Black 33 11.3 26 13.7 59 12.3 137 14.8 106 11.5
Other 11 3.8 3 1.6 14 2.9 52 5.6 28 3.0
Unknown 4 1.4 1 0.5 5 1.0 9 1.0 12 1.3
Treatment
Four cycles of AT 0 0.0 87 45.8 87 18.1 0 0.0 461 50.0
Four cycles of AC (without sequential paclitaxel) 0 0.0 103 54.2 103 21.4 0 0.0 461 50.0
AC 3 paclitaxel every 3 weeks 73 25.1 0 0.0 73 15.2 237 25.6 0 0.0
AC 3 paclitaxel once per week 86 29.6 0 0.0 86 17.9 246 26.6 0 0.0
AC 3 docetaxel every 3 weeks 66 22.7 0 0.0 66 13.7 228 24.6 0 0.0
AC 3 docetaxel once per week 66 22.7 0 0.0 66 13.7 215 23.2 0 0.0
Abbreviations: AC, doxorubicin plus cyclophosphamide; AT, doxorubicin plus paclitaxel; BC, breast cancer; HER2, human epidermal growth factor receptor 2; NA,
not available; TNBC, triple-negative breast cancer.
Lymph node status and tumor size were unknown for two patient cases; type of surgery was unknown for one patient case.
†HER2 status not available for full cohort; data presented for hormone receptor–negative subgroup.
Adams et al
2960 © 2014 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Downloaded from jco.ascopubs.org on October 21, 2015. For personal use only. No other uses without permission.
Copyright © 2014 American Society of Clinical Oncology. All rights reserved.
one of four taxane regimens after doxorubicin plus cyclophosphamide once
every 3 weeks for four cycles: taxol 175 mg/m2 once every 3 weeks for four
cycles, taxol 80mg/m2 once perweek for 12weeks, docetaxel 100mg/m2 once
every 3weeks for four cycles, or docetaxel 35/m2 once perweek for 12weeks.10
Of 926 patients with TNBC enrolled onto E1199, based on local institution
determinationof ER, PR, andHER2, 315were randomly selected for review as
guidedby theprespecifiedpoweranalysis (AppendixFigA1,onlineonly).For this
subset, ER andPRnegativity was defined by local laboratories before adoption of
theASCO/CAPguidelines andwas defined as 10% immunostaining.
Pathologic Assessment
Histopathologic analysis of percentageofTILswasperformedona single
full-face HE-stained tumor section using criteria described by Denkert et al3
and Loi et al.4 iTILs were defined as the percentage of lymphocytes in direct
contact with the tumor cells, whereas sTILs were defined as the percentage of
tumor stroma containing infiltrating lymphocytes. Areas of in situ carcinoma
and crush artifacts were not included. As proposed by Loi et al, we categorized
lymphocyte-predominant breast cancer (LPBC) as that involving  50%
lymphocytic infiltration of either tumor stroma or cell nests.
Histopathologic evaluation of TILs was jointly performed by two breast
pathologists (S.B., S.D.), who were blinded to clinical information, including
treatment allocation and outcomes. All tumors in the study were jointly
evaluated, and the results were reported in increments of 10; 0 was defined as
0% to 1%, and all other estimates were rounded up to the next highest decile
(ie, 11% to 20% represents TIL score of 20). In addition, an independent read
was performed on a subset of cases to test analytic validity.
Statistical Analyses
The prespecified primary end point for both the E2197 and E1199 trials
was DFS, defined as time from date of random assignment to date of first
recurrence,secondprimarymalignancy,ordeathresultingfromanycause,which-
everoccurredfirst.Patientswhowerealiveanddiseasefreewerecensoredatdateof
last contact. Secondary endpoints includedOSanddistant recurrence–free inter-
val (DRFI),whichweredefinedas timefromrandomassignment todeathregard-
less of cause anddistantmetastatic recurrence, respectively.
All statistical analyses were performed by one of the authors (R.G.), who
serves asheadbiostatistician forECOG.For theprimary testofDFS,TIL scores
were classified as high or low using the LPBC cutoff; groups were compared
usingCoxproportionalhazards regressionmodels stratifiedonstudy. Second-
ary analyses included DRFI and OS as well as comparing TIL scores of 0%
versus0%and forTIL scores as continuous variables.Multivariable analysis
was conductedwith known histopathologic and demographic prognostic fac-
tors using proportional hazardsmodels. Because weighted sampling was used
for selecting patient cases for central review in E2197, weighted analyses were
performed to provide valid estimates of population effects in this cohort; with
weights equal to the inverse sampling fractions, standard robust variance
estimates were used.11 This is valid for simple cohort sampling schemes12 and
forweightedCoxmodel analysis.13Aweight of 1wasused for all E1199patient
cases (because they were selected at random) and for recurrences in E2197;
nonrecurrences in E2197 were given a weight of 1.43. These sampling weights
were also used in Kaplan-Meier estimates of distribution.
The analysis plan was developed before the project commenced and
received approval by the Breast Cancer Intergroup of North America (TBCI).
Power calculations were based on results by Loi et al,4 who observed 10.5% of
TNBCs as LPBCs and estimated theDFS hazard ratio (HR) to be 0.3 (95%CI,
0.11 to 0.81). For validation, we targeted a smaller effect size (HR, 0.4) and
estimated that with 500 patient cases, assuming the distribution of TIL scores
seen by Loi et al and adjusting for weighted sampling, the study would have
83% power for an HR of 0.4 for LPBC versus non-LPBC. In addition, the
analysis of continuous sTIL scoreswouldhave80%power for a21%reduction
in the DFS hazard for each 10% increase in sTILs, for a 17.5% reduction in
E1199 and a 14% reduction in the combined group.
To test analytic validity, a random subset of 100 patient cases from the
study population was selected, and TILs were independently scored by the
pathologists. On the basis of the prespecified analysis plan, interobserver
agreement and individual agreement with the consensus read were measured
as the proportion with scores within  10 points, with exact binomial CIs.
Two-sided P values were used for all analyses. REMARK criteria7 were fol-
lowed for this study.
RESULTS
Baseline Clinical Characteristics
Tumor specimens from 506 patients (E2197, n  191; E1199,
n 315) were evaluated for lymphocytic infiltration. For 25 patient
cases, TILs could not be adequately assessed, because of either tissue
quality or tumor location within the lymph nodes. Therefore, 481
patient cases were included for analysis (E2197, n 190; E1199, n
291); their characteristics are listed in Table 1. There were no signifi-
cant differences in the examined variables between the subset used for
analysis and the corresponding target trial population based on char-
acteristics collected prospectively in the two studies, confirming a
representative selection (Table 1).
Analytic Validity
An excellent interobserver correlation was demonstrated in a
subset of 100 patient cases (evaluable, n  99). Rates of agreement
within 10 percentage points between the two pathologists were as
follows: 85%(95%CI, 76% to 91%) for sTILs and 97%(95%CI, 91%
to99%) for iTILs.Ratesof agreementbetweenpathologist oneand the
consensus read were 90% (95% CI, 82% to 95%) for sTILs and 97%
(95%CI, 91% to 99%) for iTILs. Rates of agreement between pathol-
ogist two and the consensus readwere 87%(95%CI, 79% to 93%) for
sTILs and 94%(95%CI, 87% to 98%) for iTILs. If category cut points
from the Kaplan-Meier analysis are used (not prespecified), the 
statistic showed moderate agreement between the two pathologists
(sTILs, 0.40; iTILs, 0.43).
TIL Distribution and Association With
Clinicopathologic Variables
Lymphocytic infiltrationwas observed in themajority of tumors
but was significantly greater in stromal compared with intraepithelial
Table 2. Distribution of TIL Scores
Score
Cancers With iTILs Cancers With sTILs
E1199
(n  291)
No.
E2197
(n  190)
No.
Total
(n  481) E1199
(n  291)
No.
E2197
(n  190)
No.
Total
(n  481)
No. % No. %
0 242 169 411 85 45 50 95 20
10 40 17 57 12 146 91 237 49
20 6 3 9 2 46 36 82 17
30 2 1 3  1 26 11 37 8
40 0 0 0 0 9 0 9 2
50 1 0 1  1 8 1 9 2
60 0 0 0 0 4 0 4  1
70 0 0 0 0 4 0 4  1
80 0 0 0 0 3 1 4  1
90 0 0 0 0 0 0 0 0
100 0 0 0 0 0 0 0 0
NOTE. No. of patient cases within intratumoral and stromal compartments by
study and combined with percentages of tumors.
Abbreviations: iTIL, intraepithelial tumor-infiltrating lymphocyte; sTIL, stromal
tumor-infiltrating lymphocyte; TIL, tumor-infiltrating lymphocyte.
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areas (Table 2); 80% of tumors had at least 10% sTILs (range, 10% to
80%), but only 15% of cancers had at least 10% iTILs (range, 10% to
50%). In the whole population, the median percentage of iTILs was
0% (interquartile range, 0% to 0%), which was lower than that for
sTILs (10%; interquartile range, 10% to 20%). Examples of varying
degrees of infiltration are shown in Figure 1. The correlation between
mean percentage sTIL and iTIL assessmentswas 0.47 (P .001), with
one exception; patient cases with iTILs always had stromal infiltrates.
LPBC ( 50% TILs; Fig 1) was seen in only 4.4% of TNBCs
(21 of 481). Germinal centers were noted in a small fraction of
cancers ( 1%) and not included in the analysis.
There were no strong associations between TIL scores and other
factors examined (age, menopausal status, or tumor size), with the
exception of lymph node status. The likelihood of an sTIL score of 0
decreased as the number of positive nodes increased, with a rate of
25.4% (50 of 197) for node-negative breast cancers, 18.1% (36 of 199)
BA
C
E
D
0.500.250 0.75 1.00 mm
Fig 1. Variable degree of lymphocytic infiltrate in triple-negative breast cancer on hematoxylin and eosin (HE) –stained tumor sections. Examples of tumors without
intraepithelial tumor-infiltrating lymphocytes (TILs) but varying degrees of stromal TILs by HE: (A) 0%, (B) 20%, (C) formation of germinal follicles, and (D) 80% (10
magnification). (E) Representative example of lymphocyte-predominant breast cancer (5 magnification) with 10% intraepithelial TILs (inset, black arrow, lymphocytes
in direct contact with cancer cells) and 80% stromal TILs (inset, red arrow, abundant lymphocytes within stroma).
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for tumorswithone to threepositivenodes, and10.6%(nineof85) for
tumors with three nodes (2 P .01).
Association of TILs With DFS
For the prognostic evaluations, all treatment arms were pooled.
Among the 481 patient cases, there were 190 DFS events (E1199, 118
events; E2197, 72 events), with 133 of these being recurrences (E1199,
87; E2197, 46; other events were new primary cancers and deaths
without prior recurrence). The median follow-up was 10.6 years
(E1199, 10.1 years; E2197, 12.6 years).
Continuous TIL scores were associated with DFS in univariable
analysis (sTILs, P  .02; iTILs, P  .06), with estimated HRs for a
10-point change in sTIL and iTIL scores being 0.86 (95% CI, 0.76 to
0.98; P .02) and 0.72 (95% CI, 0.51 to 1.02; P .06), respectively
(Fig 2). Because of the association of sTIL score with lymph node
involvement, which is a known prognostic factor for DFS, the sTIL
score was more significant when nodes were taken into account
(sTILs:HR, 0.82; 95%CI, 0.72 to 0.94;P .003; iTILs:HR, 0.73; 95%
CI, 0.52 to 1.02; P  .07). The intraepithelial score did not reach
significance, because most patient cases had scores of 0, even though
the estimated effect was larger. Although the analysis was only ade-
quately powered for the combined analysis for E2197 andE1199, data
are provided separately by study in Appendix Table A1 (online only).
When TILs were assessed as a binary variable ( 0 v 0), the
estimatedHRwas 0.69 (95%CI, 0.49 to 0.98; P .04) for presence of
sTILs compared with the absence of sTILs and 0.69 (95% CI, 0.45 to
1.06;P .09) for thepresenceof iTILsversus theabsenceof iTILs.The
binary analysis for LPBChad limitedpower,withonly 21patient cases
(4.4%). The estimated HR for LPBC was 0.59 (95% CI, 0.27 to 1.28;
P .18) in univariable analysis and 0.45 (95% CI, 0.19 to 1.03; P
.06) in multivariable analysis including nodal involvement.
Association of TILs With DRFI and OS
Among the 481 patient cases, 107 events of distant recurrence
and 142 deaths were reported. sTIL score was significantly correlated
with DRFI and OS. The estimated HR for a 10-point change in sTIL
score (estimated from linear term without adjustment for other fac-
tors)was 0.82 (95%CI, 0.68 to 0.99;P .04) forDRFI and 0.81 (95%
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Fig 2. Prognostic value of tumor-infiltrating lymphocytes (TILs) in triple-negative breast cancer. Kaplan-Meier curves of estimated disease-free survival (DFS) for all
patients for (A) stromal TIL (sTIL) score and (B) intraepithelial TIL (iTIL) score (grouped as 0 [defined as 0% to 1%] v 10 [2% to 10%] v 20 to 40 [11% to 40%] v 50
[41% to 50%] or v 50 to 80 [41% to 80%]); P values are for comparison of four groups.
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Fig 3. Prognostic value of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative breast cancer. Kaplan-Meier curves of estimated (A) distant recurrence–free
interval (DRFI) and (B) overall survival (OS) for all patients for sTILs (grouped as 0 [defined as 0% to 1%] v 10 [2% to 10%] v 20 to 40 [11% to 40%] v 50 to 80 [41%
to 80%]); P values are for comparison of four groups.
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CI, 0.69 to 0.95; P  .01) for OS (Fig 3). The intraepithelial score
correlated with both DRFI and OS but did not reach significance
(DRFI:HR, 0.53; 95%CI, 0.25 to 1.09;P .08;OS:HR, 0.64; 95%CI,
0.39 to 1.05; P .08).
Multivariable Analysis
Multivariable analysis including prognostic variables obtained
prospectively in both trials (tumor size, lymph node status, and age)
confirmed sTILs to be an independent prognostic factor for DFS,
DRFI, andOS (Table 3). Grade was not included in themultivariable
analysis, because itwasnotprospectively collected inE1199, andgrade
is less relevant for this subtype because most TNBCs are high grade.
However,when gradewas included for theE2197 stratum, the general
results of the multivariable analysis did not change (data not shown).
DISCUSSION
In this study, we confirmed that stromal lymphocytic infiltration
constitutes a robust and independent prognostic marker in TNBCs
treatedwith adjuvant chemotherapy, with increasing sTILs predictive
of a significantly lower risk of recurrence or death, distant recurrence,
and overall mortality. We analyzed 481 TNBC samples prospectively
collected in two phase III adjuvant randomized breast cancer trials in
the United States. At a median follow-up of 10.6 years, sTILs as a
continuous variable were associated with DFS, with an estimated HR
of0.84 (P .005) for a 10-point change in sTIL score.Associations for
iTILs and LPBC with outcome were also observed but did not reach
statistical significance, because only a small percentage of cancers
displayed these. Importantly, the prognostic significance of sTILs was
independent of known prognostic factors, and in our population of
node-positive and node-negative cancers, it improved outcome pre-
diction even more significantly when lymph node status was taken
into account. DRFI and OS, which are undoubtedly the most impor-
tant outcomemeasures for patients with TNBC, also showed a signif-
icant association with sTILs (DRFI: HR, 0.82; P .04; OS: HR, 0.81;
P .01) for each 10-point increase in sTILs.
Lymphocytic infiltration inprimarybreast cancerswasdescribed
decades ago, often in the context of medullary breast cancers,14 and
some observations suggested prognostic value.2-5,15,16 However, only
few studies used patient cases from controlled randomized trials,
including the adjuvant series by Loi et al4 and the neoadjuvant studies
by Denkert et al3 and West et al.5 Specifically, Loi et al showed that
TILs aremore frequent inTNBCs comparedwith hormone receptor–
positive breast cancers and associated with outcome in TNBCs in the
BIG 02-98 phase III trial.4 To reach level I evidence for biomarkers,
results based on retrospective analysis using archived tissues from a
randomized trial (categoryBstudy)mustbeconfirmed inan indepen-
dent randomized trial that has been designed, conducted, and ana-
lyzed in a similar manner, and the results must be equally compelling
(Simon et al6). In our confirmatory study, we used archived tissue
specimens from independent, high-quality US phase III adjuvant tri-
als with long-term follow-up and prospectively evaluated the clinical
validity of TILs. Full-face HE-stained sections were examined, and all
analyses were prespecified. In concordance with Loi et al, sTILs as a
continuous variable were associatedwith a better prognosis in TNBC.
The effect size noted by the two studies was remarkably similar, with
each10%increase in sTILsbeingassociatedwitha15%reducedriskof
relapse or death (P .025) and 17% reduced risk of death (P .023)
in the Loi study and a 14% reduced risk of relapse or death (P .02)
and 19% reduced risk of death (P  .01) in our study. Because OS
point estimates were numerically better than DFS point estimates in
both studies, it should be further studiedwhether the ability to gener-
ate an antitumor immune response also has general health benefits.
To date, the strongest association of TILs and breast cancer out-
come has been shown for TNBCs,4,15 which are poorly differentiated
tumors and therefore may contain more antigenic tumor variants
compared with other HER2-negative breast cancer subtypes. In fact,
cancer testis antigens such as MAGE-A3 and NY-ESO-1 are most
prevalent in TNBCs, as demonstrated by several groups.17,18 TILs at
diagnosis therefore likely indicate an ongoing antitumor immune
response, which can contribute to improved outcomes (as shown for
other solid tumors19,20), although underlying mechanisms such as
increased response to cytotoxics (suggested by neoadjuvant study3)
and/or eradication of micrometastatic disease have not yet been
fully investigated.
Of note, all patients in the ECOG studies and BIG 02-98 trial
receivedadjuvant anthracycline-containing chemotherapy.Theprog-
nostic utility of TILs in TNBC is therefore limited to patients who
undergo adjuvant chemotherapy. Another limitation is the low num-
ber of LPBCs, which limited the power to determine its prognostic
value. However, the continuous score will likely be most useful in
practicebecause thebinary cutoff at 50%wasarbitrary andwasmerely
chosen to highlight good outcomes of patients with extensively infil-
trated cancers, rather than to imply the existence of a distinct biologic
Table 3. Estimated DFS, DRFI, and OS in Multivariable Model for Linear Effect of Stromal TIL Score
Variable
DFS DRFI OS
HR 95% CI P HR 95% CI P HR 95% CI P
Stromal TIL (10% increase) 0.84 0.74 to 0.95 .005 0.81 0.68 to 0.97 .02 0.79 0.67 to 0.92 .003
Tumor size  2.0 v 2.1-5.0 cm 0.58 0.41 to 0.81 .002 0.51 0.31 to 0.84 .008 0.52 0.34 to 0.79 .002
Tumor size  2.0 v  5.0 cm 0.47 0.27 to 0.81 .007 0.31 0.16 to 0.61  .001 0.41 0.22 to 0.75 .004
Node negative v 1-3 lymph nodes 0.53 0.36 to 0.78 .001 0.48 0.28 to 0.82 .007 0.48 0.30 to 0.76 .002
Node negative v  3 lymph nodes 0.23 0.14 to 0.38  .001 0.20 0.11 to 0.39  .001 0.17 0.10 to 0.31  .001
Age 41-50 v 24-40 years 1.30 0.83 to 2.10 .24 1.90 0.96 to 3.70 .06 1.50 0.85 to 2.80 .15
Age 51-60 v 24-40 years 1.40 0.88 to 2.30 .15 2.30 1.20 to 4.60 .02 1.80 1.00 to 3.30 .05
Age  60 v 24-40 years 2.20 1.30 to 3.60 .003 1.90 0.88 to 4.30 .10 2.90 1.60 to 5.30  .001
Abbreviations: DFS, disease-free survival; DRFI, distant recurrence–free interval; HR, hazard ratio; OS, overall survival; TIL, tumor-infiltrating lymphocyte.
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subgroup.4 It is important to stress for the nonpathologist that al-
though sTILs are not in direct contact with cancer cells, these TILs are
still located within the tumor.
Our study raises several questions for future investigation. Does
LPBC correlate with the recently identified immunomodulatory sub-
set of TNBC?21 Can immunomodulating therapies administered at
diagnosis increase TILs and improve clinical outcome in TNBC? Can
conventional cancer therapeutics be harnessed for their induction of
immunogenic cell death?22,23 Can further delineation of infiltrating
immune-cell subsets (eg, programmed death-1 expression by lym-
phocytes, which can contribute to prognosis24) and chemokine pro-
files identify additional targets for therapies?
In conclusion,weprovide clinical validation that increasing stro-
mal lymphocytic infiltration assessed on full-section HE-stained tu-
mors on a continuous scale is a robust and independent prognostic
factor for TNBC. The results of this study as an independent category
B data set, together with the data published by Loi et al,4 provide level
I evidence of sTILs as a prognostic indicator in TNBCs treated with
adjuvant chemotherapy. This marker should therefore be considered
for prospective inclusion in clinical trials and routine histopathologic
evaluation of operable TNBCs, and efforts are ongoing to obtain
procedural standardization among several laboratories.
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GLOSSARY TERMS
biomarker (biologic marker): a characteristic that is objec-
tively measured and evaluated as an indicator of normal biologic
processes, pathogenic processes, or pharmacologic responses to a
therapeutic intervention.
cancer-testis antigens: proteins expressed on the surface of
cancer and testicular cells capable of eliciting an immune re-
sponse outside of the immunologically shielded testis.
Cox proportional hazards regressionmodel: a statis-
tical model for regression analysis of censored survival data, ex-
amining the relationship of censored survival distribution to one
or more covariates. This model produces a baseline survival
curve, covariate coefficient estimates with their standard errors,
risk ratios, 95% CIs, and significance levels.
HER2/neu (human epidermal growth factor recep-
tor 2): also called ErbB2. HER2/neu belongs to the epidermal
growth factor receptor (EGFR) family and is overexpressed in
several solid tumors. Like EGFR, it is a tyrosine kinase receptor
whose activation leads to proliferative signals within the cells. On
activation, the human epidermal growth factor family of recep-
tors are known to form homodimers and heterodimers, each
with a distinct signaling activity. Because HER2 is the preferred
dimerization partner when heterodimers are formed, it is impor-
tant for signaling through ligands specific for any members of the
family. It is typically overexpressed in several epithelial tumors.
histopathologic: the examination of a biopsy or surgical specimen
by a pathologist, after the specimen has been processed and histologic
sections have been placed onto glass slides. The vast majority of cancer
diagnoses are made by pathologists. The medical diagnosis is formulated
as a pathology report describing the histologic findings and the opinion
of the pathologist. Evaluation of the diagnosis and the prognosis is re-
quired for most treatment protocols.
neoadjuvant therapy: the administration of chemotherapy prior
to surgery. Induction chemotherapy is generally designed to decrease
the size of the tumor prior to resection and to increase the rate of com-
plete (R0) resections.
NY-ESO-1: gene coding for antigens recognized on neoplastically
transformed cells T cells; also known as CTAG1B or cancer/testis anti-
gen 1B.
REMARK criteria: guidelines for reporting tumor marker studies,
which include a statement of objectives and a description of patient
population and treatments received, biologic materials, and assay
methods. Criteria also include guidelines for reporting data, results,
and discussion.
triple-negative phenotype: breast tumors that are negative for
progesterone and estrogen and that underexpress HER2.
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Appendix
E2197
(n = 2,952)
Samples prospectively collected and 
selected for genomic analysis and 
central review for ER/PR/HER2
(n = 776)
Used for analysis (n = 190)
  Excluded as tissue not adequate (n = 1)
Available TNBC for review
(n = 191)
TNBC based on central review
(n = 250)
E1199
(n = 5,052)
Used for analysis (n = 291)
  Excluded as tissue not adequate (n = 24)
Random selection of TNBC
(n = 315)
  ER/PR negative (n = 926)
    ER/PR positive (n = 2,556)
    Not adequate (n = 33)
TNBC based on local  (n = 926)
  determination
HER2 negative based on local  (n = 3,515)
  determination
  HER2 positive (n = 997)
  HER2 not available (n = 540)
Fig A1. Flow diagram of breast cancer specimens used from E2197 and E1199. To reach sample size of 500, as required by prespecified power analysis, samples
were needed from second trial in addition to well-characterized cohort from E2197. ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PR,
progesterone receptor; TNBC, triple-negative breast cancer.
Table A1. Estimated DFS in Univariable Model for Linear Effect of TIL Scores by Study
Variable
E1199 E2197
HR 95% CI P HR 95% CI P
Stromal TIL (10% increase) 0.91 0.81 to 1.03 .14 0.71 0.51 to 0.98 .04
Intraepithelial TIL (10% increase) 0.68 0.44 to 1.05 .08 0.81 0.45 to 1.44 .47
Abbreviations: DFS, disease-free survival; HR, hazard ratio; TIL, tumor-infiltrating lymphocyte.
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